AliveCor launches AI-powered Kardia 12L ECG System in India

IMT News Desk
IMT News Desk
· 2 min read

The pocket-sized system detects 35 cardiac determinations, including heart attacks, using a reduced leadset for timely, accurate diagnosis of heart diseases  

AliveCor, the global leader in AI-powered cardiology, has launched its groundbreaking Kardia 12L electrocardiogram (ECG) system in India. Exclusively designed for use by healthcare professionals, Kardia 12L is the world’s first AI-powered, handheld 12-lead ECG system with a unique single-cable design that can detect life-threatening cardiac conditions, including heart attack, with a reduced leadset.

Kardia 12L, which has received Central Drugs Standard Control Organisation (CDSCO) approval for use in India, detects 35 cardiac determinations (14 arrhythmias and 21 morphologies). This includes serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia.

“Kardia 12L enables physicians to rapidly detect heart diseases across a wide range of healthcare settings, making this critical medical device more accessible than ever before,” said Priya Abani, CEO, AliveCor. “More importantly, the launch of the Kardia 12L ECG system in India marks a big win for physicians and patients in the country, at a time when the healthcare system has never been more constrained, or more in need of the access and efficiency this type of solution provides.”

“AliveCor’s Kardia 12L ECG System was born from our vision to leverage AI and revolutionize traditional ECG screening,” said Dr David E. Albert, Founder and Chief Medical Officer, AliveCor. “We have compelling clinical evidence that our AI, paired with our device’s reduced leadset, delivers results on par with the gold-standard ECG that are typically only available in hospital settings, democratizing access to potentially life-saving heart data.”

“The launch of Kardia 12L marks a new era in cardiac diagnostics. In a country facing a rising burden of heart disease, this innovation reflects the future of healthcare—one that is portable, powerful, and built to empower clinicians at the point of care,” said Anuj Seth, Managing Director, AliveCor India “This groundbreaking achievement underscores our unwavering commitment to providing medical-grade cardiac diagnostic capabilities to every patient in need, improving access to medical-grade care.”

Kardia 12L is battery-operated, weighs just 135 grams, and can fit in a physician’s lab coat pocket, making it significantly smaller, more portable, and more convenient than conventional 12-lead ECG machines. Its streamlined leadset also makes it less invasive for patients, who do not need to fully disrobe during a reading. The device requires minimal self-guided training and is simpler to use than standard 12-lead ECG machines.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk